

Central Serous Chorioretinopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/CC83A3A909ABEN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: CC83A3A909ABEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Central Serous Chorioretinopathy – Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Serous Chorioretinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Central Serous Chorioretinopathy Understanding

Central Serous Chorioretinopathy: Overview

Central serous Chorioretinopathy is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. Central serous Chorioretinopathy most often occurs in young and middle-aged adults. For unknown reasons, men develop this condition more commonly than women. Vision loss is usually temporary but sometimes can become chronic or recur. A complete dilated eye examination of both eyes to obtain the image of the retina. Retinal photographs may be taken to document the appearance of disease. Optical coherence tomography (OCT) is a retinal scan that is very helpful in diagnosing Central Serous Chorioretinopathy.

Fluorescein angiography is a test in which a dye is injected into a patient's arm vein and pictures are taken of each eye to detect characteristic leakage of the dye beneath the patient's retina. Several therapies have been used to treat chronic CSC, including thermal laser treatments, oral medications, and eye injections. A “cold laser,” called photodynamic therapy, is also effective and often used to focally treat the source of fluid leakage under the retina in chronic CSC. Early detection of CSC is very helpful, and most eyes with CSC can be treated successfully to avoid permanent vision loss.

'Central Serous Chorioretinopathy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Central Serous Chorioretinopathy pipeline landscape is provided which includes the disease overview and Central Serous Chorioretinopathy treatment guidelines. The assessment part of the report embraces, in depth Central Serous Chorioretinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Central Serous Chorioretinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Central Serous Chorioretinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Central Serous Chorioretinopathy.

Central Serous Chorioretinopathy Emerging Drugs Chapters

This segment of the Central Serous Chorioretinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Central Serous Chorioretinopathy Emerging Drugs

Aflibercept: Bayer

Aflibercept is a drug that is a placenta growth factor inhibitors and vascular endothelial growth factor A inhibitors. It is was originally developed by Regeneron Pharmaceuticals and later licensed to Bayer and Sanofi. It is currently in Phase II of clinical study.

Further product details are provided in the report.

Central Serous Chorioretinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Central Serous Chorioretinopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Central Serous Chorioretinopathy

There are approx. 3+ key companies which are developing the therapies for Central Serous Chorioretinopathy. The companies which have their Central Serous Chorioretinopathy drug candidates in the most advanced stage, i.e. Phase II include, Bayer.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Central Serous Chorioretinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Central Serous Chorioretinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Serous Chorioretinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Serous Chorioretinopathy drugs.

Central Serous Chorioretinopathy Report Insights

- Central Serous Chorioretinopathy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Central Serous Chorioretinopathy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Central Serous Chorioretinopathy drugs?

How many Central Serous Chorioretinopathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Serous Chorioretinopathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Central Serous Chorioretinopathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Central Serous Chorioretinopathy and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Central Serous Chorioretinopathy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

Aflibercept: Bayer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early stage products (Phase I)

Comparative Analysis

Episcleral Celecoxib: Targeted Therapy Technologies

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Inactive Products

Comparative Analysis

Central Serous Chorioretinopathy Key Companies

Central Serous Chorioretinopathy Key Products

Central Serous Chorioretinopathy- Unmet Needs

Central Serous Chorioretinopathy- Market Drivers and Barriers

Central Serous Chorioretinopathy- Future Perspectives and Conclusion

Central Serous Chorioretinopathy Analyst Views

Central Serous Chorioretinopathy Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Central Serous Chorioretinopathy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Central Serous Chorioretinopathy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Central Serous Chorioretinopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/CC83A3A909ABEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC83A3A909ABEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970